7 results about "SOD1" patented technology

Antibody or binding fragment thereof, fusion protein, or pharmaceutical composition directed against misfolded SOD1 epitope, or nucleic acid encoding the antibody or binding fragment thereof, fusion protein, or pharmaceutical composition, are described. Also provided are methods for using and manufacturing such antibody or binding fragment thereof, fusion protein, nucleic acid, or pharmaceutical composition, as well as methods of their use for treating a disorder in a human subject in need thereof.

Abstract Dosage regimens for SOD1-targeting antisense oligonucleotides, and salts thereof, are provided. These dosage regimens find use in the treatment of subjects having or at risk of developing amyotrophic lateral sclerosis. Abstract 20 26 20 53 14 06 J ul 2 02 6 A b s t r a c t 2 0 2 6 2 0 5 3 1 4 0 6 J u l 2 0 2 6

Aspects of this disclosure provide compounds, compositions, and methods for regulating the expression or activity of superoxide dismutase 1 (SOD1). In some aspects, the compounds, compositions, and methods of this disclosure can be used to reduce the expression of SOD1 mRNA in cells or animals. In some aspects, the compounds, compositions, and methods of this disclosure can be used to reduce the expression of SOD1 protein in cells or animals. In certain embodiments, the animal has a CNS-related disease, disorder, or condition.

This invention relates to the field of bioactive peptide technology, and discloses a tetrapeptide with cognitive-improving function and its applications. The primary amino acid sequence of the tetrapeptide is Lys-Gly-Phe-Pro, and its molecular weight is 489.2587 Da. The tetrapeptide of this invention can be chemically synthesized or directionally prepared from sea cucumber protease hydrolysates. The tetrapeptide of this invention exhibits cognitive-improving activity, mainly through inhibiting GABA. B The expression of R activates the cAMP / PKA / CREB signaling pathway, promotes the release of the inhibitory neurotransmitter GABA, reduces oxidative stress damage, increases the gene expression of neurotrophic factors Bdnf and Nt3, and significantly upregulates the gene expression of antioxidant enzymes Sod1 and Gpx1, thereby exerting a neuroprotective effect and improving age-induced cognitive impairment.

The present disclosure provides oligonucleotides, pharmaceutical compositions, kits, and methods of using the oligonucleotide. The oligonucleotides comprise a central nervous system (CNS) ligand. A strand of the oligonucleotides may be a therapeutic or prophylactic agent. The oligonucleotides may be able to deliver the therapeutic or prophylactic agent to a subject. The oligonucleotides may be useful in modulate (e.g., inhibiting) the expression or activity of superoxide dismutase 1 (SOD1) and in treating or preventing diseases, e.g., central nervous system (CNS) diseases, in the subject.

The present disclosure provides oligonucleotides, pharmaceutical compositions, kits, and methods of using the oligonucleotide. The oligonucleotides comprise a central nervous system (CNS) ligand. A strand of the oligonucleotides may be a therapeutic or prophylactic agent. The oligonucleotides may be able to deliver the therapeutic or prophylactic agent to a subject. The oligonucleotides may be useful in modulate (e.g., inhibiting) the expression or activity of superoxide dismutase 1 (SOD1) and in treating or preventing diseases, e.g., central nervous system (CNS) diseases, in the subject.

The present invention relates to antisense oligonucleotides that are complimentary to SOD1, leading to decreased expression of SOD1. Reduced expression of SOD1 is beneficial in medical disorders such as Amyotrophic Lateral Sclerosis.